<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The Surveillance of Rare <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancers</z:e> in Europe (RARECARE) project aims at increasing knowledge of rare <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> in Europe </plain></SENT>
<SENT sid="1" pm="."><plain>This manuscript describes the epidemiology of <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e> (MMs), taking into account the morphological characterisation of these <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We used data gathered by RARECARE on <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients diagnosed from 1995 to 2002 and archived in 64 European population-based <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> registries, followed up to 31st December 2003 or later </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: The overall annual crude incidence of MMs was 8.6 per 100,000 </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and myeloproliferative <z:hpo ids='HP_0002664'>neoplasms</z:hpo> (MPN) were most common, with incidence rates of 3.7 and 3.1 per 100,000 year respectively, followed by 1.8 for <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and myelodysplastic/myeloproliferative <z:hpo ids='HP_0002664'>neoplasms</z:hpo> (MD/MPN) and 0.1 for histiocytic and dendritic cell <z:hpo ids='HP_0002664'>neoplasms</z:hpo> (HDCN) </plain></SENT>
<SENT sid="5" pm="."><plain>The 5-year relative survival rate ranged from 18% for <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_501'>myelomonocytic leukaemia</z:mpath>, 19% for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, 29% for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and 44% for <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> to relatively favourable rates for MPN (62%) and HDCN (83%) </plain></SENT>
<SENT sid="6" pm="."><plain>Total number of new cases of MMs in the EU27 is estimated at 43,000 annually, total number of prevalent cases (1st January 2008) at 189,000 cases </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSION: MMs form a large variety of rare entities with specific characteristics </plain></SENT>
<SENT sid="8" pm="."><plain>Collection of detailed information (immunophenotype, genetic abnormalities, molecular data and clinical data) and an up-to-date classification system is essential for their surveillance, especially now that more and more targeted therapies are being introduced </plain></SENT>
</text></document>